 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H25FN6O2 |
| Molar mass | 412.469 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ro48-6791 is a drug, an imidazobenzodiazepine derivative developed byHoffman-LaRoche in the 1990s.[1]
Ro48-6791 was developed as an alternative to the short-acting imidazobenzodiazepinemidazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Ro48-6791 has properties similar to those of midazolam, being water-soluble, with a fast onset and short duration of action. It is 4-6x more potent than midazolam,[2] and slightly shorter acting,[3] and produces similar side effects such as sedation and amnesia.
It was tested up to Phase II human trials, but while it produced lessrespiratory depression thanpropofol, it had a longer recovery time and was deemed not to have any significant advantages over the older drug.[4] Similarly when Ro48-6791 was compared to midazolam, it had similar efficacy, higher potency and a shorter recovery time, but produced less of a synergistic effect on opioid-induced analgesia and produced more severe side effects such as dizziness after the procedure.[5] Consequently, it was dropped from clinical development,[6] although it is still used in scientific research.[7]
